MRK vs UPB · P/E 33, rev $16.61B vs rev $2.9M
Merck & Company Inc (MRK) versus Upstream Bio, Inc. (UPB) — a side-by-side from cached financials, not a winner call.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Rob Davis.
Upstream Bio, Inc. (UPB) is a biotechnology company listed on US.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Latest reported UPB revenue for 2025-12-31 was $2.9M. Net income was -$143.4M. Revenue was up 20.4% from 2024-12-31 to 2025-12-31. UPB currently screens at market cap $407.3M.
MRK currently screens at market cap $285.12B and trailing P/E 32.5. UPB currently screens at market cap $407.3M.
Not investment advice. Open the MRK and UPB stock pages for the full models.
Not investment advice.